Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Biondvax Pharma ADR (NQ: BVXV ) N/A UNCHANGED Last Price Updated: 3:59 PM EDT, Sep 6, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Biondvax Pharma ADR < Previous 1 2 3 4 5 6 7 8 Next > BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Encouraged by Nanosized Antibody Study Results as Market Forecasts Predict Rapid Growth February 08, 2023 Via Investor Brand Network New Model Sheds Light on Patterns of Infectious Illnesses February 07, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Animal Study Results Featured in Aegis Capital Corp. Updated Price Target February 06, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb February 06, 2023 Via Investor Brand Network Exposures COVID-19 Product Safety BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate January 23, 2023 Via Benzinga BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference February 02, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Presenting at BIO CEO & Investor Conference February 02, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Research Links Two Natural Deposits to Onset of Macular Degeneration January 31, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study January 30, 2023 Via Investor Brand Network Exposures COVID-19 Toddlers, Infants Risk Severe Outcomes When Faced with Multiple Infections January 24, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19 January 23, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study January 23, 2023 Via Investor Brand Network Exposures COVID-19 Product Safety BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study January 23, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket January 19, 2023 Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. Via Benzinga Scientists Discover Unknown T Cell Function That Can Help Fight Fungal Infections January 17, 2023 Via Investor Brand Network BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs January 17, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs January 13, 2023 Via Investor Brand Network Exposures COVID-19 Stocks That Hit 52-Week Lows On Tuesday January 10, 2023 Tuesday's session saw 16 companies set new 52-week lows. Via Benzinga America Faces Shortage of Infectious Disease Experts January 09, 2023 Via Investor Brand Network 12 Health Care Stocks Moving In Friday's After-Market Session January 06, 2023 Via Benzinga BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus January 06, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform January 06, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study January 06, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase January 05, 2023 Via Investor Brand Network Exposures COVID-19 BiondVax to Present at Biotech Showcase 2023 January 05, 2023 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements January 04, 2023 Via Investor Brand Network Exposures COVID-19 BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Letter to Shareholders January 03, 2023 Via Investor Brand Network Exposures COVID-19 Stocks That Hit 52-Week Lows On Tuesday January 03, 2023 On Tuesday, 31 stocks hit new 52-week lows. Via Benzinga BiondVax CEO Issues Letter to Shareholders December 30, 2022 From BiondVax Pharmaceuticals Ltd. Via GlobeNewswire BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market December 29, 2022 Via Investor Brand Network Exposures COVID-19 < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.